| | | |   | | | | By Helen Branswell Jim Lo Scalzo/Pool via AP Peter Marks thinks it's conceivable that the booster shot people are getting now may not be the last some will need for the coming year. Read More | | Sponsored Insight by CATALENT PHARMA SOLUTIONS How a proven development and manufacturing partner can help early-stage biotech While developing an injection drug, an up-and-coming biotech company ran into a common challenge: Injection site reactions and sub-optimal pharmacokinetics. An attempt to reformulate mitigated the injection site reaction, but the pharmacokinetics were still not where they needed to be. As a development and manufacturing partner with much experience, Catalent stepped in, suggested that rather than terminate the program or try to reformulate again, they could instead use the model-based dosing approach to explore new dosing protocols. Read more. | | By Rachel Cohrs Alex Hogan/STAT; Source photo: Melissa Lyttle for STAT Michelle McMurry-Heath’s abrupt exit from BIO shocked the biotech industry. Here’s the inside story of how her departure unfolded. Read More | | By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More | |
No comments